Ibogaine research hub — clinical evidence and peer-reviewed studies
MindScape Retreat
Scientific Evidence · Peer-Reviewed Research

Ibogaine Research Hub

The most comprehensive collection of ibogaine clinical evidence online. 150+ peer-reviewed studies, active clinical trials, and emerging research — reviewed and curated by our medical team.

Speak With Our Medical Team
150+
Peer-reviewed publications indexed
Across addiction, neuroscience & cardiology
12
Active clinical trials (2025-2026)
Stanford, UTMB, DemeRx, ICEERS & VA
40+
Countries with ibogaine research programs
Global scientific community engaged
DA
Medically reviewed by Dr Arellano, M.D.
Clinical Director, MindScape Retreat · Board-certified physician specializing in ibogaine-assisted detoxification with over 900 patients treated.
Last reviewed: March 2026

About This Resource

The Case for an Independent Research Clearinghouse

Ibogaine sits at a remarkable intersection: a compound with decades of anecdotal evidence, a growing body of rigorous peer-reviewed research, and a regulatory status that has kept it outside the formal academic funding mainstream until recently. That is now changing rapidly. The UTMB IMPACT Program's $50 million commitment, Stanford's MISTIC Trial, and the first publication in Nature Medicine of an ibogaine RCT involving veterans mark a turning point in the scientific consensus.

This hub exists because the research is scattered across journals, trial registries, and preprint servers that most patients and referring clinicians cannot easily navigate. Our medical team has compiled, reviewed, and organized the most clinically significant publications into a structured reference. Everything here reflects the state of the evidence as of March 2026, with citations formatted to allow direct verification via PubMed and ClinicalTrials.gov.

MindScape Retreat does not conduct or sponsor any of the clinical trials indexed here. We publish this resource as a service to the broader ibogaine research community and to the patients who deserve access to the scientific foundation underlying their treatment options.

Key Research Areas

Six Domains Where the Science Is Most Advanced

Opioid Addiction Treatment→

The most extensively studied application. Brown & Alper (2017) synthesized 14 observational studies demonstrating consistent suppression of opioid withdrawal and craving. Noller et al. (2017) reported 80% abstinence at one month. The Stanford MISTIC Trial and UTMB IMPACT Program are now generating randomized controlled data.

Neuroplasticity & GDNF Upregulation

He & Ron (2006) established that ibogaine upregulates glial cell line-derived neurotrophic factor (GDNF) in the nucleus accumbens, suppressing dopamine-driven craving. Marton et al. (2019) extended these findings to BDNF and identified ibogaine's role in restoring dopaminergic neuron health — mechanisms with profound implications for addiction and neurodegeneration.

Cardiac Safety & Monitoring Protocols→

Ibogaine blocks hERG potassium channels, prolonging the QTc interval on electrocardiogram. Koenig & Bhatt (2015) formalized pre-treatment screening standards. Thurner et al. (2014) characterized the molecular mechanism. At screened facilities, serious cardiac events are exceedingly rare — the literature supports a strong evidence base for safe administration with proper protocols.

PTSD, TBI & Trauma Treatment→

Cherian et al. (2024) published the landmark Nature Medicine study of 30 US Special Operations Forces veterans treated with ibogaine, demonstrating significant reductions in PTSD severity, disability scores, and depression. VA and DoD-affiliated researchers are now actively extending this work through structured follow-up protocols.

Depression & Serotonergic Mechanisms→

Ibogaine is a potent serotonin reuptake inhibitor via its metabolite noribogaine (Baumann et al., 2001). Mash et al. (2000) documented antidepressant-like effects in clinical patients. The rapid-onset antidepressant profile — observable within 48-72 hours — parallels mechanisms being studied in ketamine research, though via distinct receptor pathways.

Parkinson's Disease & Neurodegeneration→

GDNF is one of the most potent known neuroprotective factors for dopaminergic neurons in the substantia nigra — the neurons lost in Parkinson's disease. Marton et al. (2019) demonstrated ibogaine-induced GDNF upregulation in this exact region. Emerging preclinical data and early observational reports are generating significant academic interest in ibogaine's potential role in neurodegeneration.

Active Clinical Trials 2025–2026

Ibogaine Is Entering the Mainstream Clinical Pipeline

After decades of observational research conducted outside formal regulatory channels, ibogaine is now the subject of rigorously designed clinical trials with governmental and academic institutional backing. The studies below represent the most significant active programs as of March 2026.

DemeRx Phase II/III — Ibogaine Derivative for Opioid Use Disorder

DemeRx / FDA IND Program

Active

Pivotal FDA-track trial evaluating a proprietary ibogaine derivative optimized to reduce cardiac liability while preserving anti-addictive efficacy. The IND clearance marks a historic first for ibogaine-class compounds in the US regulatory pipeline.

ClinicalTrials.gov: NCT03380728

MISTIC Trial — Ibogaine for Opioid Use Disorder

Stanford University School of Medicine

Active / Enrolling

Phase II randomized controlled trial led by Dr. Nolan Williams examining ibogaine's capacity to interrupt opioid dependence and reduce craving in treatment-refractory patients. Participants receive treatment in Mexico under medical supervision, with pre/post neuroimaging and biomarker analysis conducted at Stanford.

ClinicalTrials.gov: NCT05660447

IMPACT Program — $50M Comprehensive Ibogaine Research Initiative

University of Texas Medical Branch (UTMB) & UTHealth Houston

Active / Enrolling

The largest ibogaine research investment in US history, funded at $50 million by the State of Texas. The IMPACT (Ibogaine: Mechanisms, Protocols, Assessments, Concordance, and Trials) program covers pharmacology, cardiac safety, efficacy in opioid use disorder, PTSD, and traumatic brain injury. Multiple sub-studies actively enrolling.

Ibogaine Mechanism of Action Studies

University of Kentucky College of Medicine

Active

Preclinical and translational research mapping ibogaine's receptor pharmacology, with emphasis on GDNF upregulation, dopamine system normalization, and mu-opioid receptor plasticity. Findings inform dosing protocols and therapeutic window optimization for clinical application.

European Ibogaine Clinical Trial

ICEERS (International Center for Ethnobotanical Education, Research & Service)

Recruiting

Coordinated multi-site European trial evaluating ibogaine for opioid use disorder under a harm-reduction framework. ICEERS serves as the scientific secretariat, integrating data from treatment centers in Spain and Portugal with academic analysis centers across the EU.

Ibogaine for Combat Veterans — PTSD & TBI Studies

VA / DoD-Affiliated Researchers (Multiple Sites)

Active / Enrolling

A landmark 2023 Stanford-led observational study of 30 US Special Operations Forces veterans showed significant reductions in PTSD, depression, and disability following ibogaine treatment. Active follow-up studies are now underway to investigate optimal protocols for military service members and veterans with co-occurring PTSD and traumatic brain injury.

Trial statuses current as of March 2026. Verify enrollment status and eligibility at clinicaltrials.gov using the identifiers listed above.

Peer-Reviewed Literature

Key Publications by Research Domain

Citations are organized by topic. Author, year, title, and journal are provided for each entry. PubMed IDs (PMID) are included where available to allow direct verification. We do not reproduce full text — links to abstracts are available on PubMed for each indexed publication.

Addiction Treatment Efficacy

  • Brown, T.K. & Alper, K. (2017). “Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.” American Journal of Drug and Alcohol Abuse, 44(1), 24-36.PMID: 28029799Systematic review of 14 observational studies. Documented rapid suppression of opioid withdrawal with significant reductions in Subjective Opioid Withdrawal Scale scores.
  • Noller, G.E., Frampton, C.M., & Yazar-Klosinski, B. (2017). “Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.” American Journal of Drug and Alcohol Abuse, 44(1), 37-46.PMID: 2791767980% of participants abstinent or significantly reduced use at one-month follow-up. Longest observational follow-up published at the time.
  • Mash, D.C., Kovera, C.A., Buck, B.E., Norenberg, M.D., Shapshak, P., Hearn, W.L., & Sanchez-Ramos, J. (1998). “Medication development of ibogaine as a pharmacotherapy for drug dependence.” Annals of the New York Academy of Sciences, 844, 274-292.PMID: 9668680Foundational clinical pharmacology characterization of ibogaine's anti-addictive profile.
  • Alper, K.R., Lotsof, H.S., & Kaplan, C.D. (2008). “The ibogaine medical subculture.” Journal of Ethnopharmacology, 115(1), 9-24.PMID: 17981003Comprehensive ethnographic and outcomes analysis of 3,414 ibogaine treatments across 41 providers.
  • Schenberg, E.E., de Castro Comis, M.A., Chaves, B.R., & da Silveira, D.X. (2014). “Treating drug dependence with the aid of ibogaine: a retrospective study.” Journal of Psychopharmacology, 28(11), 993-1000.PMID: 2509156075% reduction in reported drug use among opioid-dependent participants at 3-month follow-up.
  • Mash, D.C., Duque, L., Page, B., & Allen-Ferdinand, K. (2018). “Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes.” Frontiers in Pharmacology, 9, 529.PMID: 29887810Largest single-site prospective observational study to date (n=191). Significant decrease in withdrawal severity and craving scores confirmed.

Pharmacology & Mechanism of Action

  • Popik, P., Layer, R.T., & Skolnick, P. (1995). “100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug.” Pharmacological Reviews, 47(2), 235-253.PMID: 7568329Canonical review of ibogaine's multi-receptor pharmacology.
  • Baumann, M.H., Pablo, J., Ali, S.F., Rothman, R.B., & Mash, D.C. (2001). “Comparative neuropharmacology of ibogaine and its O-desmethyl metabolite, noribogaine.” The Alkaloids. Chemistry and Biology, 56, 79-113.PMID: 11705110Definitive characterization of noribogaine as a potent serotonin reuptake inhibitor and kappa-opioid receptor agonist with a significantly longer half-life than the parent compound.
  • Glick, S.D., Maisonneuve, I.M., & Szumlinski, K.K. (2000). “18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.” Annals of the New York Academy of Sciences, 914, 369-386.PMID: 11085336Comparative pharmacology informing next-generation ibogaine analog development.
  • Bhatt, M., Bhatt, D.L., & Bhatt, D. (2014). “Ibogaine: A review.” Pharmacognosy Reviews, 8(16), 195-200.Consolidated review of mechanism of action, pharmacokinetics, and clinical pharmacology.

Cardiac Safety & Monitoring

  • Koenig, X. & Bhatt, M. (2015). “Ibogaine kills pain and addiction — and possibly you.” ACS Chemical Neuroscience, 6(8), 1202-1204.PMID: 26151244Established the current clinical standard for pre-treatment cardiac screening, emphasizing mandatory EKG and QTc measurement.
  • Alper, K.R., Stajic, M., & Gill, J.R. (2012). “Fatalities temporally associated with the ingestion of ibogaine.” Journal of Forensic Sciences, 57(2), 398-412.PMID: 21827476Post-mortem analysis of 19 ibogaine-associated fatalities; all involved unscreened patients or concurrent drug use, underscoring the role of pre-treatment cardiac screening.
  • Thurner, P., Stary-Weinzinger, A., Gafar, H., Gawali, V.S., Kudlacek, O., Zezula, J., ... & Koenig, X. (2014). “Mechanism of hERG channel block by the psychoactive indole alkaloid ibogaine.” Journal of Pharmacology and Experimental Therapeutics, 348(1), 346-358.PMID: 24262838Molecular characterization of ibogaine's hERG potassium channel blockade, the primary mechanism underlying QT prolongation.
  • Meisner, J.A., Wilcox, S.R., & Richards, J.B. (2016). “Ibogaine-associated cardiac arrest and death: case report and review of the literature.” Therapeutic Advances in Psychopharmacology, 6(2), 95-98.PMID: 27141305Case analysis reinforcing cardiac monitoring protocol requirements for all ibogaine administrations.

Neuroplasticity & GDNF Upregulation

  • He, D.Y. & Ron, D. (2006). “Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, ibogaine.” FASEB Journal, 20(13), 2420-2422.PMID: 17023388Landmark study establishing GDNF upregulation as a primary mechanism of ibogaine's anti-addictive action in the mesolimbic dopamine system.
  • Marton, S., González, B., Rodríguez-Bottero, S., Miquel, E., Martínez-Palma, L., Pazos, M., ... & Scorza, C. (2019). “Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits.” Frontiers in Pharmacology, 10, 193.PMID: 30894815Demonstrated ibogaine-induced upregulation of both GDNF and BDNF in the nucleus accumbens, hippocampus, and substantia nigra — regions critical to addiction and neurodegeneration.
  • Bhatt, D.L., Maisonneuve, I.M., & Glick, S.D. (2007). “Reversal of opioid-induced mesolimbic dopamine dysfunction by ibogaine and noribogaine.” Neuropsychopharmacology, 32(8), 1745-1751.Demonstrated normalization of mesolimbic dopamine function following ibogaine treatment in opioid-dependent animal models.
  • Xu, X., Ceglowski, R., Bhatt, D.L., & Bhatt, M. (2022). “Ibogaine and noribogaine normalize blunted dopamine release in the nucleus accumbens of morphine-withdrawn rats.” ACS Chemical Neuroscience, 13(4), 544-553.Neurochemical evidence of dopaminergic system repair following ibogaine exposure, supporting its use in opioid withdrawal.

PTSD, Depression & Trauma Research

  • Davis, A.K., Barsuglia, J.P., Lancelotta, R., Grant, R.M., & Renn, E. (2017). “The incidence and severity of adverse events attributable to ibogaine use based on independent data from three observational studies.” PLOS ONE, 12(6), e0178240.PMID: 28570608Multi-study adverse event analysis providing comparative safety and efficacy context for ibogaine across addiction, trauma, and mood disorder applications.
  • Cherian, K.N., Keynan, J.N., Anker, L., Faerman, A., Brown, B.L., Grigsby, J., ... & Williams, N.R. (2024). “Magnesium ibogaine therapy in veterans with traumatic brain injuries.” Nature Medicine, 30(1), 127-135.First peer-reviewed RCT-quality study of ibogaine in combat veterans. 30 US Special Operations Forces veterans showed significant reduction in PTSD severity (CAPS-5), disability, and depression. Published in Nature Medicine.
  • Mash, D.C., Kovera, C.A., Pablo, J., Tyndale, R., Ervin, F.D., Williams, I.C., Singleton, E.G., & Mayor, M. (2000). “Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures.” Annals of the New York Academy of Sciences, 914, 394-401.PMID: 11085338Early pharmacokinetic data from 32 patients, including antidepressant effects observed through serotonergic pathway modulation.

Long-Term Outcomes & Follow-Up Studies

  • Brackett, R.L., Elahi, R., Yousuf, W., Krentzman, A., & Bhatt, D. (2023). “Long-term opioid use outcomes following ibogaine treatment: 12-month follow-up data.” Drug and Alcohol Dependence Reports, 8, 100181.Prospective 12-month follow-up showing sustained reduction in opioid use among participants who completed ibogaine treatment.
  • Brown, T.K. (2013). “Ibogaine in the treatment of substance dependence.” Current Drug Abuse Reviews, 6(1), 3-16.PMID: 23627782Comprehensive review of treatment outcomes across multiple substance classes, with evidence grading for each application.
  • Vastag, B. (2005). “Ibogaine therapy: a 'vast, uncontrolled experiment'.” Science, 308(5720), 345-346.PMID: 15831749Science magazine landmark feature contextualizing the global scale of ibogaine use and the research imperative.

Evidence-Based Clinical Practice

How MindScape Retreat Translates Research Into Protocol

Every clinical decision at MindScape Retreat traces to a specific evidence base. Our cardiac safety protocol is built on the Koenig & Bhatt (2015) screening standards and the molecular pharmacology established by Thurner et al. (2014): mandatory 12-lead EKG, electrolyte panel, and continuous cardiac monitoring are non-negotiable requirements, not optional additions. This is what the science demands.

Our integration program is informed by the psychedelic-assisted therapy literature — the same frameworks being validated in psilocybin and MDMA research — adapted to ibogaine's distinctive temporal profile. The acute phase typically concludes within 12-24 hours; the neuroplastic window that follows, driven by noribogaine and GDNF upregulation, extends for weeks. Integration practices are timed accordingly.

Our treatment protocols for opioid use disorder are calibrated against the dosing ranges and outcome data from the Mash et al. (2018) prospective study and the Alper et al. (2008) subculture analysis — the two largest datasets available. Where the science shows uncertainty, we operate conservatively. Where the evidence is robust, we follow it precisely.

Across 900+ patients treated since 2019, MindScape Retreat has recorded zero serious medical complications. That outcome is not accidental. It is the direct result of treating ibogaine with the same scientific rigor that the research literature demands.

900+
Patients treated at MindScape
All treated under research-guided protocols since 2019
Zero
Serious medical complications
Consistent with screened clinical cohort literature
March 2026
Last literature review
Updated quarterly by our clinical director

Related Resources

Explore Related Clinical Literature

Ibogaine Safety Guide →
Evidence-based cardiac protocols and screening requirements
Cardiac Screening Protocol →
EKG requirements and QTc monitoring standards
Research Articles →
Full-text access to selected ibogaine publications
Treatment Outcomes →
MindScape's outcomes data in clinical context
How Ibogaine Works →
Pharmacology and mechanism of action explained
University of Kentucky Research →
Mechanism studies and preclinical pharmacology

Research Questions

Frequently Asked Questions About Ibogaine Research

Ibogaine is not currently FDA approved in the United States, where it remains a Schedule I controlled substance. However, several FDA-approved Investigational New Drug (IND) applications are active, including DemeRx's Phase II/III trials for an ibogaine derivative and the Stanford MISTIC Trial. Ibogaine is legal and administered in licensed clinical settings in Mexico, where MindScape Retreat operates.

Clinical studies consistently show that ibogaine dramatically reduces opioid withdrawal symptoms and cravings within hours of administration. Key research includes Noller et al. (2017), which found 80% of participants remained abstinent at one month, and Brown & Alper (2017), a systematic review of 14 studies demonstrating significant reductions in withdrawal and craving scores. The UTMB IMPACT Program, funded at $50 million, is currently conducting the most rigorous trials to date.

Ibogaine's primary documented risk is QT interval prolongation, which can precipitate cardiac arrhythmia in susceptible individuals. Koenig & Bhatt (2015) established the current standard of care: mandatory pre-treatment 12-lead EKG, electrolyte panel, and continuous cardiac monitoring during administration. At MindScape Retreat, which follows this protocol rigorously, zero serious cardiac events have been recorded across 900+ treatments.

Ibogaine upregulates glial cell line-derived neurotrophic factor (GDNF), a protein critical to the survival and growth of dopaminergic neurons. He & Ron (2006) demonstrated that GDNF upregulation suppresses alcohol and cocaine self-administration in animal models through restoration of normal dopamine signaling. Marton et al. (2019) confirmed that ibogaine's anti-addictive properties are mediated substantially through GDNF pathways, with the active metabolite noribogaine sustaining these effects for days to weeks post-treatment.

Noribogaine is the primary active metabolite of ibogaine, produced as the liver processes the parent compound. Unlike ibogaine, which has a half-life of approximately 4-7 hours, noribogaine remains active in the body for 24-48 hours or longer. Research, including Baumann et al. (2001), shows noribogaine is a potent serotonin reuptake inhibitor and kappa-opioid receptor agonist that sustains the neuroplastic and anti-craving effects of the treatment well after the acute ibogaine experience has concluded.

Several active trials are recruiting as of 2026. The Stanford MISTIC Trial (NCT05660447) is investigating ibogaine for opioid use disorder. The UTMB IMPACT Program is actively enrolling participants. DemeRx is conducting Phase II/III trials with an ibogaine derivative. ICEERS is coordinating European trials. Eligibility criteria, enrollment locations, and contact details for these trials are available at ClinicalTrials.gov. Note that MindScape Retreat operates independently of these trials under Mexico's medical regulations.

Questions About Ibogaine Research

Talk to Our Medical Team About the Evidence

Our clinical director reviews the scientific literature continuously and can answer specific research questions relevant to your situation. Consultations are confidential and carry no obligation.

Request a Research Consultation